News

Generalized Anxiety Disorder Due for DSM-5 Makeover

Publish date: March 10, 2011

 

FROM THE ANNUAL PSYCHOPHARMACOLOGY REVIEW SPONSORED BY THE UNIVERSITY OF ARIZONA

Dr. Gelenberg disclosed that he serves as a consultant to several companies, including Eli Lilly, AstraZeneca, Wyeth, GlaxoSmithKline, ZARS Pharma, Jazz Pharmaceuticals, Lundbeck, Takeda, E-Research Technology, Dey Pharma, and PGxHealth.

Pages

Recommended Reading

Potential Risks to Newborns Being Added to Antipsychotics' Pregnancy Labels
MDedge Internal Medicine
Video Report: Deep Brain Stimulation for Psychiatric Disorders?
MDedge Internal Medicine
U.K. Guidelines: Sertraline First for Generalized Anxiety Disorder
MDedge Internal Medicine
U.S. Military Succeeds With Family-Based Resiliency Training
MDedge Internal Medicine
Long-Acting Risperidone No Better Than Oral Antipsychotics
MDedge Internal Medicine
Referenced EEGs May Guide Depression Treatment Better Than STAR*D Algorithm
MDedge Internal Medicine
Rural Lung Cancer Survivors Face Higher Mental Distress
MDedge Internal Medicine
Combo Beats Monotherapy in Major Depressive Disorder
MDedge Internal Medicine
Worldwide Bipolar Disorder Prevalence Estimated at 2.4%
MDedge Internal Medicine
Collaborative Depression Care Effective for Multiple Cardiac Diseases
MDedge Internal Medicine